Spero soars as UTI drug trial with partner GSK stops after early success

Spero Therapeutics

28/05/2025 12:50

** Shares of drug developer Spero Therapeutics SPRO.O jumps 241.6% to $2.33 premarket

** Co and partner GSK GSK.L to stop trial of experimental urinary tract drug tebipenem HBr due to early success after it met the main goal of a late-stage study

** The decision comes after a recommendation from an independent committee that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial

** In the trial, the drug showed it was at least as good as an existing intravenous treatment in hospitalized adult patients

** As of last close, SPRO stock down 33.8% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))